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esponsibility of InstAbstract The objective of this study was to investigate the genetic basis of high level aminoglycoside
resistance in Acinetobacter baumannii clinical isolates from Beijing, China. 173 A. baumannii clinical
isolates from hospitals in Beijing from 2006 to 2009 were ﬁrst subjected to high level aminoglycoside
resistance (HLAR, MIC to gentamicin and amikacin4512 mg/mL) phenotype selection by broth
microdilution method. The strains were then subjected to genetic basis analysis by PCR detection of
the aminoglycoside modifying enzyme genes (aac(3)-I, aac(3)-IIc, aac(60)-Ib, aac(60)-II, aph(4)-Ia, aph
(30)-I, aph(30)-IIb, aph(30)-IIIa, aph(30)-VIa, aph(2″)-Ib, aph(2″)-Ic, aph(2″)-Id, ant(2″)-Ia, ant(3″)-I and
ant(40)-Ia) and the 16S rRNA methylase genes (armA, rmtB and rmtC). Correlation analysis between the
presence of aminoglycoside resistance gene and HLAR phenotype were performed by SPSS. Totally 102
(58.96%) HLAR isolates were selected. The HLAR rates for year 2006, 2007, 2008 and 2009 were
52.63%, 65.22%, 51.11% and 70.83%, respectively. Five modifying enzyme genes (aac(3)-I, detection
rate of 65.69%; aac(60)-Ib, detection rate of 45.10%; aph(30)-I, detection rate of 47.06%; aph(30)-IIb,4
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L. Nie et al.296detection rate of 0.98%; ant(3″)-I, detection rate of 95.10%) and one methylase gene (armA, detection rate of
98.04%) were detected in the 102 A. baumannii with aac(3)-Iþaac(60)-Ibþant(3″)-IþarmA (detection rate of
25.49%), aac(3)-Iþaph(30)-Iþant(3″)-IþarmA (detection rate of 21.57%) and ant(3″)-IþarmA (detection rate
of 12.75%) being the most prevalent gene proﬁles. The values of chi-square tests showed correlation of armA,
ant(3″)-I, aac(3)-I, aph(30)-I and aac(60)-Ib with HLAR. armA had signiﬁcant correlation (contingency
coefﬁcient 0.685) and good contingency with HLAR (kappa 0.940). The high rates of HLAR may cause a
serious problem for combination therapy of aminoglycoside with β-lactams against A. baumannii infections.
As armA was reported to be able to cause high level aminoglycoside resistance to most of the clinical
important aminoglycosides (gentamicin, amikacin, tobramycin, etc), the function of aminoglycoside
modifying enzyme gene(s) in A. baumannii carrying armA deserves further investigation.
& 2014 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acinetobacter baumannii is a notorious Gram-negative pathogen found
in clinical settings due to its epidemic tendency and multidrug
resistance (MDR)1,2. It can cause serious infections like ventilator
associated pneumonia (VAP), skin and soft tissue infection, wound
infection, secondary meningitis, blood infection, etc2,3. Since A.
baumannii is commonly resistant to clinically available antimicrobial
agents, including β-lactams, aminoglycosides and ﬂuoroquinolones, the
selection of appropriate antibiotics is increasingly limited3–5.
Aminoglycosides, which bind speciﬁcally to 16S rRNA in the 30S
ribosomal subunits to inhibit protein synthesis, are often used in
combination with broad spectrum β-lactams to treat Gram-negative
bacterial infections6–8. Resistance to aminoglycosides is most com-
monly caused by aminoglycoside modifying enzymes, including
acetyltransferases, phosphotransferases and nucleotidyltransferases9,10.
More recently, 16S rRNA methylases, ArmA, RmtA, RmtB, RmtC,
RmtD, RmtE and NpmA have been reported among Enterobacter-
iaceae, Pseudomonas spp. and Acinetobacter spp.11,12. Aminoglycoside
modifying enzymes differ in aminoglycosides that they may modiﬁed,
whereas 16S rRNA methylases confer high-level resistance to almost
all aminoglycosides except streptomycin11,13,14.
The purpose of our study was to investigate the genetic basis of
high level aminoglycoside resistance in A. baumannii clinical
isolates from hospitals in Beijing, China.
2. Materials and methods
2.1. Bacterial Strains
173 A. baumannii clinical isolates collected from hospitals in
Beijing, China between 2006 and 2009 were included in the
current study, including 57 isolates in 2006, 23 isolates in 2007, 45
isolates in 2008 and 48 isolates in 2009. The strains were identiﬁed
further in our laboratory by VITEK 2-compact bacteria identiﬁca-
tion system (Bio-Merieux Company) and by sequence analysis of
the conserved region of 16S rRNA gene. Escherichia coli ATCC
25,922 and A. Baumannii ATCC 19606 were standard strains from
American Type Culture Collection (ATCC).
2.2. Antimicrobial susceptibility to gentamicin and amikacin
The antimicrobial susceptibility of the isolates to gentamicin and
amikacin were determined by microdilution method in CAMH broth(cation-adjusted Mueller–Hinton broth) according to CLSI recom-
mendation. Three concentrations (1024, 512 and 256 mg/mL) were
included in the experiment. The strains were recognized as high level
aminoglycoside resistant (HLAR) if the MICs against gentamicin
and amikacin were both higher than 512 mg/mL. E. coli ATCC
25922 and A. Baumannii ATCC 19606 were used as controls.
2.3. Polymerase chain reaction ampliﬁcation of the
aminoglycoside resistance genes
Polymerase chain reaction (PCR) was performed in a total volume of
25 mL containing one single colony, 0.6 mmol/L of each primer and
12.5 mL of 2Go Taq Green Master Mix (Promega). The genes
encoding the following aminoglycoside modifying enzymes were
investigated: acetyltransferases AAC(3)-I, AAC(3)-IIc, AAC(60)-Ib
and AAC(60)-II; phosphotransferases APH(4)-Ia, APH(30)-I, APH
(30)-IIb, APH(30)-IIIa, APH(30)-VIa, APH(2″)-Ib, APH(2″)-Ic and
APH(2″)-Id; nucleotidyltransferases ANT(2″)-Ia, ANT(3″)-I, ANT
(40)-Ia. The 16S rRNA methylase genes investigated included armA,
rmtB and rmtC. The primer sequences, expected amplicon sizes and
the annealing temperatures for PCR are shown in Table 1. The
ampliﬁcation reaction with a DNA thermal cycler (Perkin-Elmer Cetus,
Foster City, CA) consisted of a predenaturation at 95 1C for 5 min, 35
cycles of denaturation at 95 1C for 30 s, 55 or 58 1C for 30 s, extension
at 72 1C for 1 min, and a ﬁnal elongation at 72 1C for 5 min.
2.4. Correlation analysis between aminoglycoside resistance
gene and HLAR phenotype
The correlations of aminoglycoside resistance gene with HLAR
phenotype were statistically analyzed by chi-square test using
SPSS 13.0. Based on the nature of the data, Pearson's chi-square
test was used in correlation analysis of aac(3)-I, aac(60)-Ib, aph
(30)-I or ant(3″)-I with HLAR phenotype, and Fisher's exact test
was used in correlation analysis of aac(3)-IIc, aac(60)-II, aph(30)-
IIb or armA with HLAR phenotype, respectively. Correlations
were evaluated by P values. Contingency coefﬁcient and kappa
values obtained for each gene. The gene was considered correlated
with HLAR if P value o0.05, and no correlation if P value
Z0.05. Contingency coefﬁcient was used to measure the extent of
the correlation, and higher value suggested stronger correlation.
Kappa value was the scale of the correlation agreement (Z0.75,
good agreement; 0.754kappa value Z0.4, general agreement;
o0.4, poor agreement).
Table 1 The primer sequences, amplicon sizes and annealing temperatures for PCR.
Gene Primer sequence Amplicon size (bp) Annealing temperature (1C) Ref.
Aminoglycoside modifying enzyme gene
ant(2″)-Ia F: 50-GCTCACGCAACTGGTCCA GA-30 719 58 15
R: 50-GGCACGCAAGACCTCAACCT-30
ant(3″)-I F: 50-TGATTTGCTGGTTACGGTGAC-30 284 55 16
R: 50-CGCTATGTTCTCTTGCTTTTG-30
ant(40)-Ia F: 50-CTGCTAAATCGGTAGAAGC-30 172 55 17
R: 50-CAGACCAATCAACATGGCACC-30
aac(3)-I F: 50-TTACGCAGCAGCAACGATGT-30 402 58 15
R: 50-GTTGGCCTCATGCTTGAGGA-30
aac(3)-IIc F: 50-ACGCGGAAGGCAATAACGGA-30 854 55 15
R: 50-TAACCTGAAGGCTCGCAAGA-30
aac(60)-Ib F: 50-CATGACCTTGCGATGCTCTA-30 490 58 15
R: 50-GCTCGAATGCCTGGCGTCTT-30
aac(60)-II F: 50-TTCATGTCCGCGAGCACCCC-30 178 55 18
R: 50-GACTCTTCCGCCATCGCTCT-30
aph(2″)-Ib F:50-CTTGGACGCTGAGATATATGAGCAC-30 867 55 19
R:50-GTTTGTAGCAATTCAGAAACACCCTT-30
aph(2″)-Ic F: 50-CCACAATGATAATGACTCAGTTCCC-30 444 55 19
R: 50-CCACAGCTTCCGATAGCAAGAG-30
aph(2″)-Id F: 50-GTGGTTTTTACAGGAATGCCATC-30 641 55 16
R:50-CCCTCTTCATACCAATCCATATAACC-30
aph(30)-I F: 50-ATGTGCCATATTCAACGGGAAACG-30 816 55 16
R:50-TCAGAAAAACTCATCGAGCATCAA-30
aph(30)-IIb F: 50-ATGCATGATGCAGCCACCTCC-30 804 55 17
R: 50-CTAGAAGAACTCGTCCAATAGCCT-30
aph(30)-IIIa F: 50-GGCTAAAATGAGAATATCACCGG-30 278 55 17
R: 50-CTTTAAAAAATCATACAGCTCGCG-30
aph(30)-VIa F: 50-ATACAGAGACCACCATACAGT-30 234 55 16
R: 50-GGACAATCAATAATAGCAAT-30
aph(4)-Ia F: 50-CTGAACTCACCGCGACGTCT-30 977 58 15
R: 50-TCCACTATCGGCGAGTACTT-30
16S rRNA methylase gene
rmtB F: 50-GCTTTCTGCGGGCGATGTAA-30 173 55 20
R: 50-ATGCAATGCCGCGCTCGTAT-30
rmtC F: 50-CGAAGAAGTAACAGCCAAAG-30 711 55 20
R: 50-ATCCCAACATCTCTCCCACT-30
armA F: 50-ATTCTGCCTATCCTAATTGG-30 315 55 20
R: 50-ACCTATACTTTATCGTCGTC-30
Genetic basis of HLAR in A. baumannii 2973. Results and discussion
3.1. Antimicrobial susceptibility to gentamicin and amikacin
Antimicrobial susceptibility of A. baumannii to gentamicin and
amikacin was determined by broth microdilution method, and the
results are summarized in Table 2. Totally 102 isolates showed high
level aminoglycoside resistance (HLAR) with a HLAR rate of
58.96%. The HLAR rates for year 2006, 2007, 2008 and 2009 were
52.63%, 65.22%, 51.11% and 70.83%, respectively. The high rates
of HLAR might cause a serious problem for combination therapy of
aminoglycoside with β-lactams against A. baumannii infections.3.2. Polymerase chain reaction ampliﬁcation of the
aminoglycoside resistance genes
Totally 15 aminoglycoside modifying enzyme genes and three 16S
rRNA methylase genes were investigated in all of the isolates. The
results are shown in Table 3. Of the 15 aminoglycoside modifyingenzyme genes investigated, seven were detected in the current A.
baumannii isolates, with positive rates of 66.47%, 45.09%,
34.10%, 32.37%, 0.58%, 0.58% and 0.58% for ant(3″)-I, aac(3)-
I, aph(30)-I, aac(60)-Ib, aac(3)-IIc, aac(60)-II and aph(30)-IIb,
respectively. Among the positive aminoglycoside modifying
enzyme genes, ﬁve were detected in the 102 HLAR isolates, with
positive rates of 95.10%, 65.69%, 47.06%, 45.10% and 0.98% for
ant(3″)-I, aac(3)-I, aph(30)-I, aac(60)-Ib and aph(30)-IIb, respec-
tively. The high detection rates of ant(3″)-I, aac(3)-I, aph(30)-I and
aac(60)-Ib genes in the HLAR strains of our study were consistent
with those reported by Cho et al.21. Among the three methylase
genes, only armA was detected with a positive rate of 59.54% for
all the strains and 98.04% in the 102 HLAR isolates (100 out of
102 strains showed positive results). rmtB or rmtC genes were not
able to be detected in the current isolate group. These results were
also in accordance with other reports which found armA to be the
only 16S rRNA methylase gene detected in high level aminoglyco-
side resistant A. baumannii 13,14,21,22.
Aminoglycoside resistance genes were also detectable in non-
HLAR strains, though at relatively low rates. The presence of the
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L. Nie et al.298aminoglycoside resistance gene in non-HLAR strains suggested
that complicated regulation mechanisms were involved in the
onset of the HLAR phenotype.
3.3. Aminoglycoside resistance gene proﬁle
The aminoglycoside resistance gene proﬁles of the 102 HLAR A.
baumannii are shown in Table 4. As demonstrated, aac(3)-Iþaac(60)-
Ibþant(3″)-IþarmA, aac(3)-Iþaph(30)-Iþant(3″)-IþarmA and ant
(3″)-IþarmA were the most prevalent resistance gene proﬁles, with
positive rates of 25.49%, 21.57% and 12.75%, respectively. Resis-
tance gene proﬁles of secondary high detection rates were aac(3)-
Iþaac(60)-Ibþaph(30)-Iþant(3″)-IþarmA, aac(3)-Iþant(3″)-IþarmA
and aph(30)-Iþant(3″)-IþarmA, and the corresponding positive rates
were 8.82%, 7.84% and 7.84%. Other resistance gene proﬁles
included aac(60)-Ibþaph(30)-Iþant(3″)-IþarmA (detection rate of
4.90%), aph(30)-IþarmA (detection rate of 3.92%), aac(60)-Ibþant
(3″)-IþarmA (detection rate of 3.92%), aac(3)-Iþaac(60)-Ibþant
(3″)-I (detection rate of 0.98%) and aac(3)-Iþaph(30)-IIbþaac(60)-
Ibþant(3″)-IþarmA (detection rate of 0.98%).
As shown in Table 4, the methylase gene armA was detected
along with aminoglycoside modifying enzyme genes for most of
the isolates investigated except 2 (one showed positive result for
aac(3)-Iþaac(60)-Ibþant(3″)-I gene, and the other showed no
positive result for all the 18 aminoglycoside resistance genes). As
armA was reported to be able to cause high level aminoglycoside
resistance to most of the clinical important aminoglycosides
(gentamicin, amikacin, tobramycin, etc.)1, the function of amino-
glycoside modifying enzyme gene(s) in A. baumannii carrying
armA deserves further investigation. The HLAR isolate with
negative results for all of the 18 aminoglycoside resistance genes
also needs our further study.
3.4. Correlation analysis between aminoglycoside resistance
gene and HLAR phenotype
Data were statistically analyzed by chi-square test using SPSS
13.0, and the results are summarized in Table 5. The values of chi-
square test showed armA, ant(3″)-I, aac(3)-I, aph(30)-I and aac
(60)-Ib associated with HLAR. A contingency coefﬁcient of 0.685
showed that armA was signiﬁcantly correlated with HLAR. The
contingency coefﬁcients for ant(3″)-I, aac(3)-I, aph(30)-I and aac
(60)-Ib were 0.588, 0.444, 0.311 and 0.310, respectively. Kappa
values were further used to scale the correlation agreement.
Among the 5 correlative genes, armA had good contingency
(kappa value of 0.940), ant(3″)-I and aac(3)-I had general
contingency (kappa values of 0.717 and 0.477), whereas aph(30)-
I and aac(60)-Ib had poor consistency (kappa values of 0.289 and
0.282).4. Conclusions
A. baumannii clinical isolates collected between 2006 and 2009
from the hospitals in Beijing, China showed high levels of
aminoglycoside resistance. Several resistance genes were detected
in A. baumannii clinical isolates, and coexistence of resistance
genes was found in most strains. Correlation analysis demonstrated
that armA gene was closely related to HLAR. The high rates of
HLAR in these clinical isolates may cause a serious problem for
combination therapy of aminoglycoside with β-lactams against A.
baumannii infections.
Table 5 Correlation analysis between aminoglycoside resistance gene and HLAR (chi-square test).
Aminoglycoside resistant genes P value Contingency coefﬁcient Kappa value
armA 0.000 0.685 0.940
aac(3)-I 0.000 0.444 0.477
aac(3)-IIc 0.410 0.091 0.012
aac(60)-Ib 0.000 0.310 0.282
aac(60)-II 0.410 0.091 0.012
aph(30)-I 0.000 0.311 0.289
aph(30)-IIb 1.000 0.063 0.008
ant(3″)-I 0.000 0.588 0.717
Table 4 Aminoglycoside resistance gene proﬁles of the 102 HLAR Acinetobacter baumannii.
Aminoglycoside resistance gene proﬁle No. of isolate Positive rate (%)
aac(3)-Iþ aac(60)-Ibþant(3″)-IþarmA 26 25.49
aac(3)-Iþ aph(30)-Iþant(3″)-IþarmA 22 21.57
ant(3″)-IþarmA 13 12.75
aac(3)-Iþaac(60)-Ibþaph(30)-Iþant(3″)-IþarmA 9 8.82
aac(3)-Iþant(3″)-IþarmA 8 7.84
aph(30)-Iþant(3″)-IþarmA 8 7.84
aac(60)-Ibþaph(30)-Iþant(3″)-IþarmA 5 4.90
aph(30)-IþarmA 4 3.92
aac(60)-Ibþant(3″)-IþarmA 4 3.92
aac(3)-Iþaac(60)-Ibþant(3″)-I 1 0.98
aac(3)-Iþ aph(30)-IIbþaac(60)-Ibþant(3″)-IþarmA 1 0.98
None of 18 aminoglycoside resistance genes 1 0.98
Table 3 Distribution of aminoglycoside resistance genes in 173 Acinetobacter baumannii isolates.
Result Aminoglycoside resistant genes
armA aac(3)-I aac(3)-IIc aac(60)-Ib aac(60)-II aph(30)-I aph(30)-IIb ant(3″)-I
Positive isolates from HLAR 100 67 0 46 0 48 1 97
Positive rate from HLAR (%) 98.04 65.69 0 45.10 0 47.06 0.98 95.10
Positive isolates from non-HLAR 3 11 1 10 1 11 0 18
Positive rate from non-HLAR (%) 4.23 15.49 1.41 14.08 1.41 15.49 0 25.35
Total positive isolates 103 78 1 56 1 59 1 115
Positive rate (%) 59.54 45.09 0.58 32.37 0.58 34.10 0.58 66.47
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